Save The Date: Oxurion to host Virtual R&D Investor Day on 15 October 2020
05 Ottobre 2020 - 10:00AM
Save The Date: Oxurion to host Virtual R&D Investor Day on 15
October 2020
SAVE THE DATE:
Oxurion to host Virtual R&D
Investor Day on 15 October 2020
Leuven, Belgium, October 5, 2020 – 10 am
CET – Oxurion NV (Euronext Brussels: OXUR), a
biopharmaceutical company developing next generation
standard-of-care therapies for diabetic macular edema (DME), will
host a virtual R&D Investor Day on the
15 October 2020 at 5.30pm CET/ 4.30pm BST/ 11.30am
ET.
The meeting, intended for investors and
analysts, will provide an overview of the Company’s development
pipeline and corporate strategy, which is focused on successfully
creating an industry leading DME franchise.
Oxurion is currently developing THR-149 and
THR-687, two novel drug candidates with non-VEGF modes of action,
which together have the potential to deliver a new standard of care
for all patients with DME.
Presentations will be delivered by members of
Oxurion’s senior management team and by two global Key
Opinion Leaders in the field of retinal vascular
disorders:
- Ramin Tadayoni, M.D., Ph.D. is Professor of
ophthalmology at University of Paris. He is head of the
Ophthalmology Departments at Lariboisière, St Louis and Rothschild
Foundation Hospitals in Paris, France.
- Arshad Khanani, M.D., M.A., is Managing
Partner, Director of Clinical Research, Director of Fellowship at
Sierra Eye Associates, and Clinical Associate Professor at the
University of Nevada, Reno, US.
The agenda and details of how to join the
meeting will be available in an invitation and on the Company’s
website (www.Oxurion.com) which will be issued closer to the time
of the event.
END
For further information please contact:
Oxurion NVWouter Piepers, Global Head of Investor Relations&
Corporate CommunicationsTel: +32 16 75 13 10 / +32 478 33 56
32wouter.piepers@oxurion.com |
Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/ Frazer HallTel:
+44 20 7638 9571oxurion@citigatedewerogerson.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to better preserve
vision in patients with diabetic macular edema (DME), the leading
cause of vision loss in diabetic patients worldwide.
Oxurion is building a leading global franchise
in the treatment of DME, based on the successful development of its
two novel therapeutics:
- THR-149, a plasma kallikrein inhibitor being developed as a
potential new standard of care for DME patients who respond
sub-optimally to anti-VEGF therapy.THR-149 has shown positive
topline Phase 1 results for the treatment of DME. The Company
is currently conducting a Phase 2 clinical trial evaluating THR-149
with DME-patients who previously responded sub-optimally to
anti-VEGF therapy. THR-149 was developed in conjunction with
Bicycle Therapeutics PLC (NASDAQ: BCYC)
- THR-687, is a pan-RGD integrin inhibitor, that is initially
being developed as a potential new standard of care for all DME
patients. Positive topline results in a Phase 1 clinical study
assessing it as a treatment for DME were announced in January 2020.
THR-687 is expected to enter a Phase 2 clinical trial by
mid-2021. THR-687 is an optimized compound derived from a
broader library of integrin inhibitors in-licensed from Galapagos
NV (Euronext & NASDAQ: GLPG).
Oxurion is headquartered in Leuven, Belgium, and is listed on
the Euronext Brussels exchange under the symbol OXUR.
More information is available at
www.oxurion.com.
Important information about
forward-looking statementsCertain statements in this press
release may be considered “forward-looking”. Such forward-looking
statements are based on current expectations, and, accordingly,
entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such
forward-looking statements will materialize and does not assume an
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or any other
reason. Additional information concerning risks and uncertainties
affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is
contained in the Company’s Annual Report. This press release does
not constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities laws.
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Apr 2023 a Apr 2024